Browse GTF2H1

Summary
SymbolGTF2H1
Namegeneral transcription factor IIH, polypeptide 1, 62kDa
Aliases general transcription factor IIH, polypeptide 1 (62kD subunit); TFB1; BTF2 p62; TFIIH basal transcription fa ......
Chromosomal Location11p15.1-p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus.
Domain PF03909 BSD domain
PF08567 TFIIH p62 subunit
Function

Component of the general transcription and DNA repair factor IIH (TFIIH) core complex, which is involved in general and transcription-coupled nucleotide excision repair (NER) of damaged DNA and, when complexed to CAK, in RNA transcription by RNA polymerase II. In NER, TFIIH acts by opening DNA around the lesion to allow the excision of the damaged oligonucleotide and its replacement by a new DNA fragment. In transcription, TFIIH has an essential role in transcription initiation. When the pre-initiation complex (PIC) has been established, TFIIH is required for promoter opening and promoter escape. Phosphorylation of the C-terminal tail (CTD) of the largest subunit of RNA polymerase II by the kinase module CAK controls the initiation of transcription.

> Gene Ontology
 
Biological Process GO:0000079 regulation of cyclin-dependent protein serine/threonine kinase activity
GO:0000717 nucleotide-excision repair, DNA duplex unwinding
GO:0006283 transcription-coupled nucleotide-excision repair
GO:0006289 nucleotide-excision repair
GO:0006293 nucleotide-excision repair, preincision complex stabilization
GO:0006294 nucleotide-excision repair, preincision complex assembly
GO:0006295 nucleotide-excision repair, DNA incision, 3'-to lesion
GO:0006296 nucleotide-excision repair, DNA incision, 5'-to lesion
GO:0006352 DNA-templated transcription, initiation
GO:0006353 DNA-templated transcription, termination
GO:0006354 DNA-templated transcription, elongation
GO:0006360 transcription from RNA polymerase I promoter
GO:0006361 transcription initiation from RNA polymerase I promoter
GO:0006362 transcription elongation from RNA polymerase I promoter
GO:0006363 termination of RNA polymerase I transcription
GO:0006367 transcription initiation from RNA polymerase II promoter
GO:0006368 transcription elongation from RNA polymerase II promoter
GO:0006370 7-methylguanosine mRNA capping
GO:0006397 mRNA processing
GO:0009452 7-methylguanosine RNA capping
GO:0031334 positive regulation of protein complex assembly
GO:0032392 DNA geometric change
GO:0032508 DNA duplex unwinding
GO:0033683 nucleotide-excision repair, DNA incision
GO:0036260 RNA capping
GO:0043254 regulation of protein complex assembly
GO:0044089 positive regulation of cellular component biogenesis
GO:0065004 protein-DNA complex assembly
GO:0070816 phosphorylation of RNA polymerase II C-terminal domain
GO:0070911 global genome nucleotide-excision repair
GO:0071103 DNA conformation change
GO:0071824 protein-DNA complex subunit organization
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0090305 nucleic acid phosphodiester bond hydrolysis
GO:1904029 regulation of cyclin-dependent protein kinase activity
Molecular Function GO:0003682 chromatin binding
GO:0004674 protein serine/threonine kinase activity
GO:0008094 DNA-dependent ATPase activity
GO:0008353 RNA polymerase II carboxy-terminal domain kinase activity
GO:0016887 ATPase activity
GO:0042623 ATPase activity, coupled
Cellular Component GO:0000428 DNA-directed RNA polymerase complex
GO:0000439 core TFIIH complex
GO:0005667 transcription factor complex
GO:0005675 holo TFIIH complex
GO:0016591 DNA-directed RNA polymerase II, holoenzyme
GO:0030880 RNA polymerase complex
GO:0032806 carboxy-terminal domain protein kinase complex
GO:0044798 nuclear transcription factor complex
GO:0055029 nuclear DNA-directed RNA polymerase complex
GO:0061695 transferase complex, transferring phosphorus-containing groups
GO:0090575 RNA polymerase II transcription factor complex
GO:1902554 serine/threonine protein kinase complex
GO:1902911 protein kinase complex
> KEGG and Reactome Pathway
 
KEGG hsa03022 Basal transcription factors
hsa03420 Nucleotide excision repair
Reactome R-HSA-73894: DNA Repair
R-HSA-1643685: Disease
R-HSA-5696400: Dual Incision in GG-NER
R-HSA-6782135: Dual incision in TC-NER
R-HSA-212165: Epigenetic regulation of gene expression
R-HSA-167152: Formation of HIV elongation complex in the absence of HIV Tat
R-HSA-167200: Formation of HIV-1 elongation complex containing HIV-1 Tat
R-HSA-5696395: Formation of Incision Complex in GG-NER
R-HSA-112382: Formation of RNA Pol II elongation complex
R-HSA-6781823: Formation of TC-NER Pre-Incision Complex
R-HSA-113418: Formation of the Early Elongation Complex
R-HSA-167158: Formation of the HIV-1 Early Elongation Complex
R-HSA-6782210: Gap-filling DNA repair synthesis and ligation in TC-NER
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-5696399: Global Genome Nucleotide Excision Repair (GG-NER)
R-HSA-162906: HIV Infection
R-HSA-162587: HIV Life Cycle
R-HSA-167169: HIV Transcription Elongation
R-HSA-167161: HIV Transcription Initiation
R-HSA-5663205: Infectious disease
R-HSA-162599: Late Phase of HIV Life Cycle
R-HSA-5250941: Negative epigenetic regulation of rRNA expression
R-HSA-427413: NoRC negatively regulates rRNA expression
R-HSA-5696398: Nucleotide Excision Repair
R-HSA-77075: RNA Pol II CTD phosphorylation and interaction with CE
R-HSA-167160: RNA Pol II CTD phosphorylation and interaction with CE during HIV infection
R-HSA-73777: RNA Polymerase I Chain Elongation
R-HSA-73854: RNA Polymerase I Promoter Clearance
R-HSA-73772: RNA Polymerase I Promoter Escape
R-HSA-73864: RNA Polymerase I Transcription
R-HSA-73762: RNA Polymerase I Transcription Initiation
R-HSA-73863: RNA Polymerase I Transcription Termination
R-HSA-504046: RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
R-HSA-167162: RNA Polymerase II HIV Promoter Escape
R-HSA-674695: RNA Polymerase II Pre-transcription Events
R-HSA-73776: RNA Polymerase II Promoter Escape
R-HSA-73857: RNA Polymerase II Transcription
R-HSA-75955: RNA Polymerase II Transcription Elongation
R-HSA-75953: RNA Polymerase II Transcription Initiation
R-HSA-76042: RNA Polymerase II Transcription Initiation And Promoter Clearance
R-HSA-73779: RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
R-HSA-6796648: TP53 Regulates Transcription of DNA Repair Genes
R-HSA-167246: Tat-mediated elongation of the HIV-1 transcript
R-HSA-167172: Transcription of the HIV genome
R-HSA-6781827: Transcription-Coupled Nucleotide Excision Repair (TC-NER)
R-HSA-3700989: Transcriptional Regulation by TP53
R-HSA-72086: mRNA Capping
Summary
SymbolGTF2H1
Namegeneral transcription factor IIH, polypeptide 1, 62kDa
Aliases general transcription factor IIH, polypeptide 1 (62kD subunit); TFB1; BTF2 p62; TFIIH basal transcription fa ......
Chromosomal Location11p15.1-p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between GTF2H1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolGTF2H1
Namegeneral transcription factor IIH, polypeptide 1, 62kDa
Aliases general transcription factor IIH, polypeptide 1 (62kD subunit); TFB1; BTF2 p62; TFIIH basal transcription fa ......
Chromosomal Location11p15.1-p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of GTF2H1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen Total # shRNA with >= 4-fold: 1 Resistant to T-cell proliferation
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolGTF2H1
Namegeneral transcription factor IIH, polypeptide 1, 62kDa
Aliases general transcription factor IIH, polypeptide 1 (62kD subunit); TFB1; BTF2 p62; TFIIH basal transcription fa ......
Chromosomal Location11p15.1-p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of GTF2H1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2710.298
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.6730.712
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0250.986
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2560.464
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.8140.622
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4470.827
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1190.746
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0110.995
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2390.9
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.2740.84
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.480.804
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.010.849
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of GTF2H1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolGTF2H1
Namegeneral transcription factor IIH, polypeptide 1, 62kDa
Aliases general transcription factor IIH, polypeptide 1 (62kD subunit); TFB1; BTF2 p62; TFIIH basal transcription fa ......
Chromosomal Location11p15.1-p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of GTF2H1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolGTF2H1
Namegeneral transcription factor IIH, polypeptide 1, 62kDa
Aliases general transcription factor IIH, polypeptide 1 (62kD subunit); TFB1; BTF2 p62; TFIIH basal transcription fa ......
Chromosomal Location11p15.1-p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of GTF2H1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by GTF2H1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolGTF2H1
Namegeneral transcription factor IIH, polypeptide 1, 62kDa
Aliases general transcription factor IIH, polypeptide 1 (62kD subunit); TFB1; BTF2 p62; TFIIH basal transcription fa ......
Chromosomal Location11p15.1-p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of GTF2H1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolGTF2H1
Namegeneral transcription factor IIH, polypeptide 1, 62kDa
Aliases general transcription factor IIH, polypeptide 1 (62kD subunit); TFB1; BTF2 p62; TFIIH basal transcription fa ......
Chromosomal Location11p15.1-p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of GTF2H1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolGTF2H1
Namegeneral transcription factor IIH, polypeptide 1, 62kDa
Aliases general transcription factor IIH, polypeptide 1 (62kD subunit); TFB1; BTF2 p62; TFIIH basal transcription fa ......
Chromosomal Location11p15.1-p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between GTF2H1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolGTF2H1
Namegeneral transcription factor IIH, polypeptide 1, 62kDa
Aliases general transcription factor IIH, polypeptide 1 (62kD subunit); TFB1; BTF2 p62; TFIIH basal transcription fa ......
Chromosomal Location11p15.1-p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting GTF2H1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.